Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs

W H Bisson, A V Cheltsov, N Bruey-Sedano, B Lin, J Chen, N Goldberger, Lauren Therese May, Arthur Christopoulos, J T Dalton, Patrick Sexton, X-K Zhang, Ruben Abagyan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Finding good drug leads de novo from large chemical libraries, real or virtual, is not an easy task. High-throughput screening is often plagued by low hit rates and many leads that are toxic or exhibit poor bioavailability. Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles. Here, we describe an efficient computational methodology to discover leads to a protein target from safe marketed drugs. We applied an in silico drug repurposing procedure for identification of nonsteroidal antagonists against the human androgen receptor (AR), using multiple predicted models of an antagonist-bound receptor. The library of marketed oral drugs was then docked into the best-performing models, and the 11 selected compounds with the highest docking score were tested in vitro for AR binding and antagonism of dihydrotestosterone-induced AR transactivation. The phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagonists. This in vitro biological activity correlated well with endocrine side effects observed in individuals taking these medications. Further computational optimization of phenothiazines, combined with in vitro screening, led to the identification of a nonsteroidal antiandrogen with improved AR antagonism and marked reduction in affinity for dopaminergic and serotonergic receptors that are the primary target of phenothiazine antipsychotics.
Original languageEnglish
Pages (from-to)11927 - 11932
Number of pages6
JournalProceedings of the National Academy of Sciences
Volume104
Issue number29
Publication statusPublished - 2007

Cite this

Bisson, W. H., Cheltsov, A. V., Bruey-Sedano, N., Lin, B., Chen, J., Goldberger, N., ... Abagyan, R. (2007). Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences, 104(29), 11927 - 11932.
Bisson, W H ; Cheltsov, A V ; Bruey-Sedano, N ; Lin, B ; Chen, J ; Goldberger, N ; May, Lauren Therese ; Christopoulos, Arthur ; Dalton, J T ; Sexton, Patrick ; Zhang, X-K ; Abagyan, Ruben. / Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. In: Proceedings of the National Academy of Sciences. 2007 ; Vol. 104, No. 29. pp. 11927 - 11932.
@article{4ab5184e065c4bce902c131cb5f497ea,
title = "Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs",
abstract = "Finding good drug leads de novo from large chemical libraries, real or virtual, is not an easy task. High-throughput screening is often plagued by low hit rates and many leads that are toxic or exhibit poor bioavailability. Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles. Here, we describe an efficient computational methodology to discover leads to a protein target from safe marketed drugs. We applied an in silico drug repurposing procedure for identification of nonsteroidal antagonists against the human androgen receptor (AR), using multiple predicted models of an antagonist-bound receptor. The library of marketed oral drugs was then docked into the best-performing models, and the 11 selected compounds with the highest docking score were tested in vitro for AR binding and antagonism of dihydrotestosterone-induced AR transactivation. The phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagonists. This in vitro biological activity correlated well with endocrine side effects observed in individuals taking these medications. Further computational optimization of phenothiazines, combined with in vitro screening, led to the identification of a nonsteroidal antiandrogen with improved AR antagonism and marked reduction in affinity for dopaminergic and serotonergic receptors that are the primary target of phenothiazine antipsychotics.",
author = "Bisson, {W H} and Cheltsov, {A V} and N Bruey-Sedano and B Lin and J Chen and N Goldberger and May, {Lauren Therese} and Arthur Christopoulos and Dalton, {J T} and Patrick Sexton and X-K Zhang and Ruben Abagyan",
year = "2007",
language = "English",
volume = "104",
pages = "11927 -- 11932",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "29",

}

Bisson, WH, Cheltsov, AV, Bruey-Sedano, N, Lin, B, Chen, J, Goldberger, N, May, LT, Christopoulos, A, Dalton, JT, Sexton, P, Zhang, X-K & Abagyan, R 2007, 'Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs', Proceedings of the National Academy of Sciences, vol. 104, no. 29, pp. 11927 - 11932.

Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. / Bisson, W H; Cheltsov, A V; Bruey-Sedano, N; Lin, B; Chen, J; Goldberger, N; May, Lauren Therese; Christopoulos, Arthur; Dalton, J T; Sexton, Patrick; Zhang, X-K; Abagyan, Ruben.

In: Proceedings of the National Academy of Sciences, Vol. 104, No. 29, 2007, p. 11927 - 11932.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs

AU - Bisson, W H

AU - Cheltsov, A V

AU - Bruey-Sedano, N

AU - Lin, B

AU - Chen, J

AU - Goldberger, N

AU - May, Lauren Therese

AU - Christopoulos, Arthur

AU - Dalton, J T

AU - Sexton, Patrick

AU - Zhang, X-K

AU - Abagyan, Ruben

PY - 2007

Y1 - 2007

N2 - Finding good drug leads de novo from large chemical libraries, real or virtual, is not an easy task. High-throughput screening is often plagued by low hit rates and many leads that are toxic or exhibit poor bioavailability. Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles. Here, we describe an efficient computational methodology to discover leads to a protein target from safe marketed drugs. We applied an in silico drug repurposing procedure for identification of nonsteroidal antagonists against the human androgen receptor (AR), using multiple predicted models of an antagonist-bound receptor. The library of marketed oral drugs was then docked into the best-performing models, and the 11 selected compounds with the highest docking score were tested in vitro for AR binding and antagonism of dihydrotestosterone-induced AR transactivation. The phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagonists. This in vitro biological activity correlated well with endocrine side effects observed in individuals taking these medications. Further computational optimization of phenothiazines, combined with in vitro screening, led to the identification of a nonsteroidal antiandrogen with improved AR antagonism and marked reduction in affinity for dopaminergic and serotonergic receptors that are the primary target of phenothiazine antipsychotics.

AB - Finding good drug leads de novo from large chemical libraries, real or virtual, is not an easy task. High-throughput screening is often plagued by low hit rates and many leads that are toxic or exhibit poor bioavailability. Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles. Here, we describe an efficient computational methodology to discover leads to a protein target from safe marketed drugs. We applied an in silico drug repurposing procedure for identification of nonsteroidal antagonists against the human androgen receptor (AR), using multiple predicted models of an antagonist-bound receptor. The library of marketed oral drugs was then docked into the best-performing models, and the 11 selected compounds with the highest docking score were tested in vitro for AR binding and antagonism of dihydrotestosterone-induced AR transactivation. The phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagonists. This in vitro biological activity correlated well with endocrine side effects observed in individuals taking these medications. Further computational optimization of phenothiazines, combined with in vitro screening, led to the identification of a nonsteroidal antiandrogen with improved AR antagonism and marked reduction in affinity for dopaminergic and serotonergic receptors that are the primary target of phenothiazine antipsychotics.

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17606915

M3 - Article

VL - 104

SP - 11927

EP - 11932

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 29

ER -

Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N et al. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences. 2007;104(29):11927 - 11932.